The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis  by Shepherd, Trevor G. et al.
Research Paper 1739
The pea3 subfamily ets genes are required for HER2/Neu-
mediated mammary oncogenesis
Trevor G. Shepherd, Lisa Kockeritz, Michelle R. Szrajber, William J. Muller
and John A. Hassell
Background: The PEA3 Ets transcription factor is overexpressed in the Address: Institute for Molecular Biology and
Biotechnology, McMaster University, 1280 Mainvast majority of human breast tumors and in nearly all of those of the
Street, Hamilton, Ontario L8S 4K1, Canada.HER2/Neu-positive subclass. PEA3 is also overexpressed in various
transgenic mouse models of this disease. Whether PEA3 plays an
Correspondence: John A. Hassell
essential role in HER2/Neu-mediated oncogenesis has heretofore not been E-mail: hassell@mcmaster.ca
addressed.
Received: 28 August 2001
Revised: 17 September 2001Results: Here, we report that each of the three highly related ets genes of
Accepted: 19 September 2001the pea3 subfamily (pea3, er81, and erm) were coordinately overexpressed
in mammary tumors of MMTV-neu transgenic mice. Other ets genes normally
Published: 13 November 2001expressed in the mammary gland were not upregulated in these tumors.
Expression of a dominant-negative pea3 transgene under the control of the
Current Biology 2001, 11:1739–1748
MMTV promoter in mammary epithelial cells of MMTV-neu transgenic mice
dramatically delayed the onset of mammary tumors and reduced the number 0960-9822/01/$ – see front matter
and size of such tumors in individual mice. Those tumors that arose in  2001 Elsevier Science Ltd. All rights reserved.
bitransgenic mice expressed the MMTV-neu transgene, but not the MMTV-
dominant-negative pea3 transgene.
Conclusions: These findings imply that one or more of the PEA3 subfamily
Ets proteins or other Ets proteins with related DNA binding specificity play an
essential role in Neu-mediated mammary oncogenesis. Hence, agents that
inhibit the expression or activity of the PEA3 subfamily proteins may prove
efficacious in the treatment of breast cancer.
Background and/or overexpression is associated with multiple malig-
The HER2 gene (also known as c-erbB2 and neu) is ampli- nancies [13].
fied and/or overexpressed in several human malignancies,
including breast cancer [1], and is linked with an increased We showed previously that PEA3 is invariably overex-
propensity of such tumors to metastasize, resulting in a pressed in mammary tumors of transgenic mice that ex-
poor prognosis for the patient [2]. Increased expression press thewild-type rat neu cDNAunder the transcriptional
of HER2 in breast tumors is also correlated with a poor control of the MMTV promoter (MMTV-neu) [14]. PEA3
response to hormonal and chemotherapeutic agents [3–5]. is similarly overexpressed in 76% of all human breast
TheHER2 gene encodes a receptor tyrosine kinase struc- tumors; 93% of the HER2-positive subclass of such tu-
turally related to the epidermal growth factor receptor mors, which represent 20%–30% of all breast tumors [2],
family proteins, which act through downstream signaling overexpress PEA3 [15]. Here, we show that all three pea3
modules, including the Ras and phosphoinositide subfamily ets genes are coordinately upregulated in mam-
3-kinase pathways, to alter gene expression [1]. mary epithelial tumor cells of MMTV-neu transgenic
mice, but other ets genes, including those commonly ex-
Mouse pea3 (the human gene is named E1A-F and ETV4) pressed in the mouse mammary gland, are not. Interfer-
is the founding member of the pea3 subfamily of ets genes, ence with PEA3 subfamily protein function in mammary
which also include er81 (ETV1) and erm (ETV5) [6–11]. epithelial cells of MMTV-neu transgenic mice delayed
Ets proteins share conserved winged helix-turn-helix the onset and progression of mammary tumors, suggesting
ETS DNA binding domains comprising approximately a required role for these Ets proteins in oncogenesis.
85 amino acids [12]. These proteins bind to sequence
elements bearing a centrally located conserved 5-GGA, Results
A/T-3 motif; the DNA binding specificity of individual PEA3 is overexpressed in mouse mammary epithelial
tumor cellsEts proteins is dictated by sequences flanking this core.
Whereas PEA3 is overexpressed in mouse mammary tu-Commonly, Ets proteins activate transcription, but some
mors appearing in mice bearing the MMTV-neu trans-members of the family repress this process. Ets proteins
play key roles in embryonic development; their mutation gene, the cellular expression profile of PEA3 in these
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Figure 1tumors has not been assessed. To this end, we made use
of mice bearing a mutation in the pea3 gene; such mice
harbor a deletion in the pea3 gene, which is replaced by
sequences representing an internal ribosome entry site
and a nuclear localization signal linked to Escherichia coli
-galactosidase (nlslacZ) (Figure 1a). This mutant pea3
allele (pea3nlslacZ) is nearly identical in structure to that
described previously; it only differs from the latter by the
presence of sequences encoding lacZ at the site of the
deletion in the pea3 gene [16].Mice homozygous for either
pea3 loss-of-function allele are viable; males are sterile,
but the reproductive capacity of females is normal [16].
The profile of lacZ expression (-galactosidase activity)
in pea3nlslacZ/ mutant embryos and adults mimics that of
the wild-type pea3 gene.
To assess the expression of the pea3nlslacZ allele in mouse
mammary tumors, we derived offspring from crosses be-
tween pea3nlslacZ/mutant mice and MMTV-neu transgenic
mice. The N#202 MMTV-neu transgenic strain, used
throughout this study, bears the wild-type Neu cDNA.
Mammary tumors arise in this transgenic strain due to
deletions in sequences encoding the extracellular region
of Neu [17], resulting in constitutive dimerization and
consequent activation of its tyrosine kinase activity [18].
We prepared mammary gland whole mounts from the
transgenic pea3nlslacZ/ female mice bearing mammary tu-
mors and incubated these with X-gal to detect -galactosi-
dase activity. Multiple distinct tumor masses expressing
-galactosidase were readily apparent (Figure 1b). To ex-
amine the cellular expression profile of the mutant pea3
allele, we incubated mammary tumors from MMTV-neu
transgenic mice bearing either wild-type or a mutant pea3
allele with X-gal and prepared serial sections. These sec-
tions were either stained with hematoxylin-eosin (Figure
1c,d) or processed without subsequent staining (Figure
1e,f). -galactosidase activity was not detected in mam-
mary tumors from mice bearing wild-type pea3 alleles
(Figure 1c,e), but -galactosidase activity was present at
high levels in the mammary tumor cells from MMTV-
neu transgenic mice harboring a mutant pea3 allele (Figure PEA3 is expressed in mouse mammary tumor cells of MMTV-neu
1d,f). The stromal cells (principally fibroblasts and adipo- transgenic mice. (a) Targeted knockin of a nuclear-localized
-galactosidase reporter gene into the pea3 locus. (b) An X-gal-stainedcytes) surrounding the mammary tumors of pea3nlslacZ/
whole mount of the number 4 inguinal mammary gland isolated frommice did not express -galactosidase activity, but the nor-
a tumor-bearing MMTV-neu/pea3nlslacZ/ virgin female mouse. The
mal epithelial cells adjacent to the tumors expressed this arrows identify select mammary tumors. (c–f) Tissue sections of
activity at low levels (Figure 1f). Hence, PEA3 was selec- X-gal-stained mammary tumors isolated from either (c,e) MMTV-neu/
pea3/ or (d,f) MMTV-neu/pea3nlslacZ/ transgenic mice were (c,d)tively overexpressed in mammary epithelial tumor cells,
stained with hematoxylin and eosin or (e,f) mounted immediately afterthe same cells that express theMMTV-neu transgene [19].
incubation with X-gal. The scale bars represent 1 mm in (b) and 100
m in (c)–(f).
The pea3 subfamily genes are coordinately
overexpressed in Neu-induced tumors
To determine whether ets genes other than pea3 are ex-
pressed in the mammary gland and overexpressed in neu transgenic mice. We prepared cDNA from the RNA
mammary tumors, we compared the spectrum of Ets tran- samples, amplified these with pairs of degenerate oligonu-
scripts in RNA samples from two normal mammary glands cleotide primers complementary to ETS domain se-
quences, and cloned and sequenced 400 independentof virgin mice and from two mammary tumors of MMTV-
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Figure 2
PEA3 subfamily transcripts are increased in
MMTV-neu-induced mammary tumors. (a)
PEA3, ERM, and ER81 transcripts are
expressed at low levels in the normal, virgin
mouse mammary gland from either the FVB/N
strain (FVB) or from asymptomatic MMTV-
neu transgenic mice (Tg) but are increased
substantially in mammary tumors (T1–T6)
that arose in the MMTV-neu transgenic mice.
A multiplex RNase protection assay was
performed using riboprobes specific to mouse
PEA3, ERM, and ER81 mRNA; mouse rpL32
was used as an internal control for RNA
loading. (b) The PEA3 subfamily transcripts
are increased in the MMTV-neu tumor samples
compared to the normal mammary gland
controls from either the nontransgenic FVB/N
strain (FVB) or from asymptomatic MMTV-
neu transgenic mice (Tg). Relative PEA3
subfamily transcript abundance was quantified
by PhosphorImager analysis and was
normalized to that of rpL32. The normalized
abundance of each PEA3 subfamily transcript
in the FVB/N samples was set to 1. (c) The
abundance of Ets-1, Ets-2, and GABP-
mRNA levels is reduced in mammary tumors
arising in the MMTV-neu transgenic mice. A
multiplex RNase protection assay was
performed using riboprobes specific to mouse
Ets-1, Ets-2, and GABP- mRNA; rpL32 was
used as an internal control for RNA loading. autoradiogram. (d) Quantification of the tissue relative to that of the internal control
All the lanes in this panel were derived abundance of Ets-1, Ets-2, and GAPB- transcript, rpL32. Transcript abundance was
from the same exposure of the original transcripts in normal and mammary tumor quantified as described above.
cDNAs (92 or more cDNAs from each RNA source). We also examined the transcript levels of three other ets
genes (ets-1, ets-2, and gabp-) in another set of similarPEA3, ER81, ERM, GABP-, Ets-1, Ets-2, Elf, and Tel
samples (Figure 2c,d). These three ets genes were ex-cDNAs were readily isolated from all the samples. ER81
pressed at the same or greater levels than those of pea3,and ERM cDNAs were recovered at much higher fre-
er81, and erm in the normal mammary gland samples. Thequencies from the tumor samples than from the normal
abundance of the Ets-1, Ets-2, and GABP- transcriptssamples, suggesting that er81 and erm were overexpressed
were reduced in the tumor samples compared to the nor-in mammary tumors compared to normal mammary tissue
mal mammary glands. The reduced expression of these(data not shown).
ets genes in the tumor samplesmay reflect their downregu-
lation in epithelial tumor cells. Alternatively, these genes
To investigate this potential, we compared PEA3, ER81, may normally be expressed in nonepithelial cells; their
and ERM transcript levels in normal mammary gland apparent reduced expression in tumor tissue may reflect
samples with those in several mammary tumor samples the reduced contribution of these stromal cells to the
from MMTV-neu transgenic mice by multiplex ribo- tumor mass compared to the normal mammary gland.
nuclease (RNase) protection analysis (Figure 2a,b). All Whatever the explanation, these data suggest that, among
three PEA3 subfamily transcripts were coordinately over- the ets gene transcripts examined, those of the pea3 sub-
expressed in independent mammary tumors. The varia- family were selectively upregulated in Neu-induced
tion in the extent of overexpression of these transcripts mouse mammary tumors.
among the tumors may reflect the cellular heterogeneity
of the tumors. Mammary tumors comprise principally epi- Dominant-negative PEA3 inhibits Neu-induced
thelial tumor cells, but multiple normal nonepithelial and tumorigenesis
epithelial cell types are intimately associated with the To learn whether the pea3 subfamily ets genes play an
tumormass or contaminate themargins of dissected tumor essential role in Neu-mediated mammary oncogenesis in
samples. The contribution of these cells to the tumor mice, we tested the capacity of a dominant-negative allele
mass, particularly of small tumors, can affect quantifica- of pea3 to affect this process. To this end, we deleted
sequences encoding the activation domain of PEA3 [20]tion of transcript levels intrinsic to the tumor cells.
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Figure 3 and appended sequences coding for the repression do-
main from the Drosophila melanogaster Engrailed (En) pro-
tein to derive NPEA3En (Figure 3a). Previous analyses
of a similar Myb-En fusion protein demonstrated that
such proteins interfere with Myb function in specific tis-
sues of transgenic mice [21].
To ensure that NPEA3En functioned as expected, we
assessed its capacity to affect reporter gene expression
from two different PEA3-responsive reporters in transient
transfection experiments. One reporter bears an artificial
promoter comprising repeats of an optimal PEA3 binding
site juxtaposed to aTATAbox, whereas the other contains
the urokinase plasminogen activator (uPA) enhancer/pro-
moter. We assessed the capacity of NPEA3En to affect
expression of luciferase from these reporters in mouse
FM3A cells, which express high endogenous levels of
PEA3 [6].NPEA3En reduced expression of both report-
ers in a dose-dependent fashion in these cells (Figure
3b). We also assayed the capacity of NPEA3En to affect
PEA3 subfamily-activated reporter gene expression in
COS-1 cells, which do not express PEA3 at detectable
levels [6]. NPEA3En suppressed PEA3-, ERM-, and
ER81-activated luciferase expression in a dose-dependent
fashion, suggesting that it can compromise the function
of all three PEA3 subfamily proteins (Figure 3c). Western
immunoblotting experiments revealed that the doses of
NPEA3En used in these experiments did not affect
expression of PEA3, ERM, or ER81 from the pCANmyc
vectors encoding these proteins (Figure 3d). NPEA3En
cells. Different DNA doses (25–100 ng) of the pCANmyc vector
encoding NPEA3En or the empty expression vector (pCANmyc)
were transfected as described in the Materials and methods. (c)
Dominant-negative PEA3 reduces the capacity of PEA3, ERM, and
ER81 to activate luciferase expression from the 5xPEA3-luc reporter
plasmid in COS-1 cells in a dose-dependent fashion. The pCANmyc
expression vector was used to effect the expression of NPEA3En,
PEA3, ERM, and ER81; the empty expression vector (pCANmyc)
was also independently transfected in these experiments to serve as
a control. Increasing doses (25–250 ng) of the appropriate
expression vector were transfected as described in the Materials and
methods. The basal luciferase activity resulting from transfection of
the reporter plasmid with the empty expression vectors was set at 1.
(d) A representative immunoblot illustrating the abundance of PEA3,
ERM, ER81, and NPEA3En in a single experiment. Each of these
proteins bears an amino-terminal c-Myc epitope; their abundance
was simultaneously determined on the same immunoblot with a
monoclonal antibody directed against this epitope. (e) Dominant-
negative PEA3 does not affect GAL4-VP16-mediated activation of a
GAL4-responsive luciferase reporter plasmid in COS-1 cells. COS-1Dominant-negative PEA3 reduces PEA3 subfamily protein function in
cells were transfected with a fixed amount of the expression vectorcell culture in a dose-dependent fashion. (a) Structure of PEA3 and
encoding GAL4-VP16 and with increasing doses (25–250 ng) ofof NPEA3En. PEA3 encompasses a strong activation domain within
the pCANmyc/NPEA3En expression vector as described in theits amino terminus (light gray box) and an ETS DNA binding domain
Materials and methods. The basal luciferase activity resulting from(hatched box) near its carboxyl terminus. NPEA3En possesses a
transfection of the reporter plasmid with the empty expression vectorsMyc epitope at its amino terminus (black box) coupled to a PEA3
was set at 1. (f) A representative immunoblot illustrating thecarboxyl-terminal fragment bearing the ETS domain (hatched box) and
abundance of NPEA3En in a single experiment. The abundance ofthe Drosophila Engrailed repression domain (residues 2–298; dark
the Myc-tagged NPEA3En protein was assessed with agray box). (b) Expression of luciferase from the 3xPEA3-luc and uPA-
monoclonal antibody directed against the c-Myc epitope.luc PEA3-responsive reporters is repressed in a dose-dependent
fashion by NPEA3En in mouse FM3A mammary adenocarcinoma
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Figure 4was specific in its ability to inhibit the function of the
PEA3 subfamily proteins because it was unable to repress
GAL4-VP16-mediated expression of luciferase from a
GAL4-responsive luciferase reporter, which does not con-
tain PEA3 binding sites (Figure 3e). Western immu-
noblotting experiments showed that NPEA3En was ex-
pressed in a dose-dependentmanner in these experiments
(Figure 3f) to levels equivalent to those required to nearly
completely repress PEA3-, ERM-, or ER81-activated lu-
ciferase expression from the PEA3-responsive reporter in
the same COS cells (Figure 3d,f). These observations
suggest that NPEA3En inhibited the function of the
PEA3 subfamily proteins likely by competing for their
binding sites in the PEA3-responsive promoter of the
reporter.
To determine whether NPEA3En could similarly affect NPEA3En delays mammary tumor onset in MMTV-neu/NPEA3En
bitransgenic mice. Virgin female mice bearing either the MMTV-neuPEA3 subfamily protein function in mammary epithelial
transgene (dark line) or the MMTV-neu and MMTV-NPEA3Encells of transgenic mice, we placed the coding sequences
transgenes (thin line) were palpated for mammary tumors weekly.for this protein under the transcriptional control of the
MMTV promoter and used the resulting DNA to derive
independent transgenic founder strains. One transgenic
strain, which expressed NPEA3En transcripts in organs (n  14) of the bitransgenic mice 2 months after the
characteristic of the tissue specificity of the MMTV pro- primary tumor was detected (Table 1). By contrast, the
moter, was used in subsequent experiments. The mam- bitransgenic strain developed multiple tumors far less fre-
mary glands of both virgin and lactating female mice of quently: only 21% (n  14) of the mice developed two
this strain expressed NPEA3 transcripts at high levels or more tumors during this time frame. We noted upon
relative to other organs. Whole-mount analyses of the autopsy that the primary tumors in the bitransgenic mice
mammary glands of the MMTV-NPEA3En mice re- were generally smaller 2 months after they were initially
vealed no obvious developmental abnormalities during detected than those in the MMTV-neu transgenic strain.
postnatal mammary gland development. Thesemice nursed To quantify this difference, we weighed the mammary
their pups, and the pups grew at normal rates, suggesting tumors arising in each transgenic strain 2 months after
that the expression of NPEA3En in the mammary gland they were first detected. The mean weight of tumors
did not affect the function of this organ. arising in the MMTV-neu strain was 3.0 g (n  13),
whereas that of the tumors in the bitransgenic strain was
To learn whether the expression of NPEA3En affected 1.8 g (n 14) (Table 1). Primary mammary tumors arising
mammary oncogenesis, we monitored the time of the in the MMTV-neu strain metastasize to the lungs at high
appearance of mammary tumors in nulliparous fe- frequency [22]. However, we did not detect a statistically
male offspring resulting from crosses between MMTV- significant difference in the percentage of mice bearing
NPEA3En and MMTV-neu transgenic mice. We com- lung metastases 2 months after the primary tumors arose
pared the time of onset of mammary tumors in the between the two transgenic strains (Table 1). Collec-
MMTV-neu/NPEA3En bitransgenic mice with that in tively, these observations suggest that the expression of
MMTV-neu transgenic mice (Figure 4). Tumors occurred NPEA3En in the mammary glands of MMTV-neu trans-
in 50% of the MMTV-neu transgenic mice by 315 days genic mice delayed the appearance of mammary tumors
of age, but 575 days were required for tumors to appear and reduced their number and growth in individual mice.
in 50% of the bitransgenic mice. This difference is statisti-
cally significant, as determined by the log-rank test (p 
To determine whether Neu and NPEA3En transcripts0.003). By the end of the experiment (700 days), approxi-
were expressed in mammary tumors in the bitransgenicmately 75% of the mice in both cohorts developed mam-
mice, we carried out RNase protection analysis (Figuremary tumors.
5a). Neu transcripts were generally overexpressed in
mammary tumors compared to unaffected contralateralMultiple tumors arise in different mammary glands of the
mammary glands from the same mice, in keeping withMMTV-neu transgenic mice [17]. Generally, additional
previous findings [17, 22]. The incidence of transgeneindependent tumors appear and progress during the
deletions leading to constitutive activation of Neu was2-month period after the primary tumor is first detected
by palpation. Two or more tumors were found in 71% the same in the MMTV-neu and the bitransgenic mice,
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Table 1
Summary of tumor data from studies of MMTV-neu and MMTV-neu/NPEA3En transgenic mice.
Number of tumors per mouse (%)bTumor onset Primary tumor Percentage of
Strain (days)a 1 	2 mass (g) 
 SDc lung metastasesd
MMTV-neu 315 4/14 (28.6) 10/14 (71.4) 2.96 
 1.54 (n  13) 33.3 (n  15)
MMTV-neu/NPEA3En 575 11/14 (78.6) 3/14 (21.4) 1.77 
 1.07 (n  14) 45.4 (n  11)
a The median age of tumor onset as scored by identification of a tumors is statistically significant (p  0.02) as determined by the
palpable tumor. Student’s t test.
b The number of tumors present at the end of the 2 months subsequent d The percentage of mammary tumor-bearing mice, which also
to initial identification of a tumor. Mice were grouped into those possessed lung metastases, was determined by analyzing
having a single mammary tumor (1) versus those having two or more multiple haematoxylin- and eosin-stained tissue sections of the lungs
(	2) tumors. The difference is statistically significant (p  2 months after initial palpation of the mammary tumor. The number of
0.0039) as determined by the one-sided z test. metastatic lesions per lung was not assessed because these were
c The weight of the earliest arising mammary tumor was measured. too numerous to be accurately enumerated at this time.
The difference between MMTV-neu and MMTV-neu/NPEA3En
suggesting that expression ofNPEA3 in the bitransgenic ner to repress transcription from a complex viral promoter
bearing EBS in Neu-transformed mammary epithelial tu-mice did not affect this process (data not shown).
mor cells.
Surprisingly, NPEA3En transcripts were not expressed
or were expressed at much lower levels in the mammary Discussion
The pea3 subfamily genes were coordinately overex-tumors compared to the normal contralateral mammary
gland of the same mouse. Indeed, NPEA3En was only pressed in Neu-induced mouse mammary tumors. Three
other ets genes, ets-1, ets-2, and gabp-, which are normallyexpressed in the mammary tumors from two of seven
mice examined (T2 and T7) and then only at levels sub- expressed in the mammary gland, were not overexpressed
in mammary tumors, suggesting that upregulation of thestantially lower than those observed in the histologically
normal mammary glands contralateral to the tumors. The pea3 subfamily genes was specific. The genes comprising
the pea3 subfamily have an identical architecture, stronglyfact that NPEA3En was not generally expressed in the
mammary tumors strongly suggests that this protein inter- suggesting that they arose from a common ancestral gene
[25]. Hence, these genes may also share common pro-fered with Neu-induced mammary oncogenesis. Like
mammary tumors of MMTV-neu transgenic mice, those moter elements; Neu may regulate the activity of tran-
scription factors that bind to these sites, thus accountingarising in the bitransgenic mice also overexpressed PEA3
compared to the normal control mammary tissue (data not for their coordinate overexpression in mammary tumors.
This hypothesis is supported by the observation that in-shown).
duction of the oncogenically activated Raf kinase, which
is known to act downstream of Neu, leads to the upreg-The core sequence (5-GGA, A/T-3) characteristic of Ets
protein binding sites (EBS) is present in the MMTV ulation of pea3 transcripts in human mammary epithelial
cells [26].promoter [23], and the Ets-protein, GABP-, can activate
transcription from the MMTV promoter dependent on
these sites [24]. Hence, it is formally possible that The expression of dominant-negative PEA3 under the
aegis of the MMTV promoter in mammary epithelial cellsNPEA3En can bind to these sites when expressed at
high levels and thereby repress neu transgene expression, delayed the onset of mammary tumors, reduced the num-
ber of such tumors in individual mice, and retarded thethus affecting mammary oncogenesis. To explore this po-
tential, we used a mammary epithelial cell line (NDL) growth of these tumors in the bitransgenic strain. Tumors
arising in the bitransgenic mice did not express thederived from a mammary tumor of an MMTV-neu trans-
genic mouse. The NDL cell line supported high-level MMTV-NPEA3En transgene or expressed it at low lev-
els. These observations are consistent with a requirementexpression of anMMTV-luciferase reporter plasmid (Fig-
ure 5b). Independent cotransfection of an expression vec- for one or another PEA3 subfamily Ets protein for Neu-
mediated mammary oncogenesis.tor encoding either PEA3 or NPEA3En with the
MMTV-luciferase reporter did not affect expression of
luciferase under conditions in which both proteins were The requirement to extinguish NPEA3En function in
Neu-positive mammary epithelial cells to ensure theirexpressed to high levels in these cells (Figure 5b,c).
Hence, it seems unlikely that either PEA3 or NPEA3En progression to malignancy likely accounts for the delayed
onset and the reduced size and incidence of multiplebinds to the EBS in the MMTV promoter even when
they are overexpressed. These experiments also illustrate tumors in the bitransgenic mice. We imagine that both
the MMTV-neu and MMTV-NPEA3En transgenes arethat NPEA3En did not function in a nonselective man-
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Figure 5 may be due to the episodic reexpression of NPEA3En
in mammary tumors between the time these tumors first
arise and are palpable and the time of sacrifice of the
mice 2 months later. It is noteworthy that the expression
of transgenes is unstable [19, 27].
It is formally possible that the effect of NPEA3En on
Neu-mediated tumor progression in the bitransgenic
mice resulted from the inhibition of transcription of the
MMTV-neu transgene. NPEA3En may bind directly to
EBS in the MMTV promoter and thereby inhibit neu
transgene transcription or it may act indirectly to nega-
tively affect expression of the neu transgene in bitrans-
genic mice. Such a model would require that the two
MMTV transgenes respond differently to NPEA3En
despite the fact that the same promoter regulates expres-
sion of each transgene in the same cell. Both the MMTV-
NPEA3En and MMTV-neu transgenes were expressed
in the normal contralateral glands of tumor-bearing bitrans-
genic mice and in the normal mammary glands of asymp-
tomatic bitransgenic mice, suggesting that they can be
coexpressed in mammary epithelial cells. Furthermore,
we could not repress MMTV reporter gene expression by
overexpression of NPEA3En, nor could we activate this
reporter by expression of PEA3 in Neu-transformed
mouse mammary tumor cells despite the occurrence of
EBS in the MMTV promoter. Hence, we think it is
unlikely that NPEA3En represses expression of the
MMTV-neu transgene in mammary tumor cells and that
this accounts for its effect on mammary oncogenesis.
(a) Expression of the MMTV-NPEA3En transgene is reduced or
Recently, Xing et al. [28] reported that PEA3 suppressesundetectable in mammary tumors arising in MMTV-neu/NPEA3En
bitransgenic mice. (b) Increasing amounts of either PEA3 or HER2 promoter activity in transient transfection experi-
NPEA3En do not affect luciferase expression from the MMTV ments in two different human tumor-derived cell lines
promoter in NDL mouse mammary tumor cells. The basal luciferase
dependent on the occurrence of a PEA3 binding site inactivity resulting from transfection of the reporter plasmid with the
empty expression vector was set at 100%. (c) A representative this promoter and inhibits the capacity of these cell lines
immunoblot illustrating the abundance of PEA3 and NPEA3En in to form tumors in nude mice. These investigators sug-
a single experiment. The abundance of these Myc-tagged proteins gested that PEA3 functions to repress transcription of thewas assessed with a monoclonal antibody directed against the c-Myc
endogenous HER2 gene, thereby reverting the trans-epitope.
formed phenotype of these tumor cell lines, and offered
the prospect that PEA3 might prove efficacious either
alone or in combination with other agents to combat
HER2-positive human tumors. By contrast, in additioninitially expressed in the epithelial cells of the origin
to others, we have observed that PEA3, ERM, and ER81of mammary tumors. Oncogenesis is likely initiated by
are each capable of activating the expression of reportermutations in the neu transgene in rare epithelial cells, but
genes coupled to PEA3-responsive promoters, includingthe progression of these cells to full malignancy may be
the humanHER2 promoter in various cell types includingretarded by NPEA3En. This barrier to tumor progres-
mammary epithelial tumor cells ([6, 20, 29–31]; this re-sion may be breached in rare epithelial cells expressing
port). We have noted, however, that the expression ofboth transgenes by a genetic or an epigenetic mechanism
these same reporter genes is inhibited when each of thethat results in reduced NPEA3En expression and func-
PEA3 subfamily proteins is expressed at high levels. Wetion. The need to block NPEA3En expression in initi-
suspect that transcriptional squelching accounts for theseated tumor cells, a condition that is not required for tumors
observations. These findings coupled with our previousto arise in the MMTV-neu transgenic strain, likely ac-
observations demonstrating increased PEA3 transcriptcounts for the long delay in time to progression and inci-
levels in both mouse [14] and human [15] HER2/Neu-dence of mammary tumors in the bitransgenic mice. The
reduced size ofmammary tumors in the bitransgenic strain positive mammary tumors and those reported herein
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the GAL4-VP16 expression vector, and the 5xGAL4-luc reporter plasmidstrongly suggest that use of PEA3 as a therapeutic agent
have been described previously [20]. The MMTV-luc reporter was con-is contraindicated.
structed by isolating the luciferase gene from pGL3-Basic and cloning
it into the MMTV-SV40 plasmid [22]. To generate MMTV-NPEA3En/
Conclusions SV40pA, the DNA encoding NPEA3En was isolated from pCANmyc/
NPEA3En and was cloned into the MMTV-SV40 plasmid. The sequenceWe hypothesize that PEA3 subfamily function is required
of the DNA primers and details concerning the construction of the expres-for Neu-mediated mammary oncogenesis. This hypothe-
sion and reporter vectors are available from the authors upon request.sis is consistent with the finding that PEA3 subfamily The PEA3 riboprobe template encompasses nucleotides 1445–1941
transcripts were overexpressed in nearly all HER2/Neu- of mouse PEA3 cDNA cloned into pBluescriptIIKS. The plasmid was
linearized with BamHI to generate an antisense PEA3 RNA probe usingpositive mammary tumors and with the observation that
T3 RNA polymerase and was used to detect PEA3 and NPEA3Enabrogating PEA3 subfamily function in the mammary
transcripts. The ERM riboprobe template encompasses nucleotidesgland suppressed Neu-mediated mammary oncogenesis.
162–438 of mouse ERM cDNA cloned into pSL301 (Stratagene); it was
Whereas the inhibitory dominant-negative PEA3 protein linearized with HindIII to generate an antisense ERM RNA probe using T3
may compromise the function of Ets proteins with DNA RNA polymerase. The ER81 riboprobe template encompasses nucleotides
945–1197 of mouse ER81 cDNA cloned into pBluescriptIIKS; it wasbinding specificity related to that of the PEA3 subfamily
linearized with HindIII to generate an antisense ER81 probe using T7 RNAmembers, there is no evidence to suggest that Ets tran-
polymerase. The Ets-1 riboprobe template encompasses nucleotides
scription factors other than those of the PEA3 subfamily 135–787 cloned into pBluescriptIIKS; it was linearized with XhoI to
are overexpressed in mammary tumors. Hence, it seems generate an antisense Ets-1 RNA probe using T7 RNA polymerase. The
Ets-2 riboprobe template (a gift from Dr. Robert Oshima) has beenlikely that PEA3 Ets subfamily function is required for
described previously [35]; this DNA was linearized with EcoRI to gener-mammary oncogenesis. PEA3 is also overexpressed in
ate an antisense Ets-2 RNA probe using SP6 RNA polymerase. Themammary tumors induced byWnt-1 [32] inMMTV-Wnt-1 GABP- riboprobe encompasses nucleotides 690–975 of mouse
transgenic mice and in intestinal tumors of multiple intes- GABP- cloned into pBluescriptIIKS. The plasmid was linearized with
tinal neoplasia (Min) mice, which harbor inactivating mu- BamHI to generate an antisense GABP- RNA probe using T3 RNA
polymerase. The rpL32 riboprobe template has been described pre-tations in the adenomatous polyposis coli (Apc) tumor
viously [14]; it was linearized with XbaI to generate an antisense rpL32suppressor gene [31]. Wnt-1 signals through the Wnt/
RNA probe using T3 RNA polymerase. The MMTV-neu riboprobe tem-
-catenin pathway, which includes Apc as one of its signal- plate has been described previously [17]; it was linearized with SmaI to
ing elements, to effect oncogenesis in these two mouse generate an antisense Neu RNA probe using T7 RNA polymerase.
strains. Hence, PEA3 and other members of the PEA3
Ets subfamily may play key roles in oncogenesis initiated Cell culture and transient transfections
by multiple signaling pathways, including the Neu/Ras Cell lines were cultured as described previously [6, 20]. Transient trans-
fections were carried out using LipofectAMINE Reagent (Life Technolo-and Wnt/-catenin pathways, which are dysregulated in
gies). FM3A cells were seeded at 5  105 cells per 35-mm well thediverse malignancies. Consequently, we propose that
day prior to transfection. A total of 0.1 g reporter plasmid (3xPEA3-agents that inhibit the expression or function of PEA3
luc or uPA-luc) was cotransfected with varying amounts of either pCAN-
and its close relatives ER81 and ERM, or of their target myc or the pCANmyc/NPEA3En expression plasmid. The cells were
genes, may prove efficacious in the treatment of Neu/ lysed 24 hr posttransfection using Reporter Lysis Buffer, and luciferase
assays were performed using Luciferase Assay Reagent (Promega) andHER2-positive tumors and perhaps other tumors in hu-
a Lumat luminometer (Berthold, Perkin Elmer). Luciferase activity wasmans characterized by PEA3 subfamily overexpression.
normalized to the total protein concentration of the lysates, which were
assessed using the Bradford assay kit (Bio-Rad). COS-1 cell transfec-
Materials and methods tions and analyses of luciferase activity were performed similarly, except
for the following modifications. A total of 1.25  105 cells were seededDNA constructs
The pCANmyc expression vector (a gift from Dr. Paul Polakis) bears the the day prior to transfection, and 0.25 g 5xPEA3-luc reporter was
human cytomegalovirus promoter upstream of sequences encoding an cotransfected with either 0.025 g pCANmyc/PEA3, 0.25 g pCAN-
epitope endogenous to the c-Myc protein [33]. The molecular cloning myc/ERM, or 1 g pCANmyc/ER81. Similarly, 0.1 g 5xGAL4-luc re-
and expression of cDNAs downstream of the c-Myc epitope leads to porter and 0.25 g GAL4-VP16 effector plasmid were transfected into
the synthesis of fusion proteins bearing this epitope at their amino termini. COS-1 cells. Transient transfections of the mouse mammary epithelial
PCANmyc/NPEA3En was constructed by PCR amplification of se- NDL tumor cell line was carried out as described above after seeding
quences encoding amino acids 334–480 of mouse PEA3 cDNA using 2.5  105 cells per plate a day earlier; 0.5 g MMTV-luc reporter was
the RSV-PEA3 expression plasmid [20] and the pSCDMSMenT plasmid used with varying amounts of the effector DNAs encoding PEA3 or
(a gift from Dr. Ali Fattaey) bearing the Drosphila repression domain as NPEA3En.
templates. pCANmyc/PEA3 was isolated by cloning full-length mouse
PEA3 cDNA from pGEM7PEA3 into pCANmyc1. Full-length mouse ERM
Western immunoblottingcDNA was isolated by RT-PCR using mouse mammary tumor RNA and
Protein isolation from transfected cells and immunoblotting were per-was cloned into pCANmyc1. Full-length mouse ER81 cDNA was isolated
formed essentially as described previously [20]. Total protein (40 g)by PCR of ER81 sequences from pBS/ER81 (a gift from Dr. Tom Jessell)
from COS-1 cells and from NDL cells (100 g) was separated on aand was cloned into the pCANmyc1 expression vector to generate
10% SDS-polyacrylamide gel prior to transfer. Proteins was detectedpCANmyc/ER81. The DNA sequence of all recombinant plasmids was
using the anti-9E10 c-myc monoclonal antibody and goat anti-mousedetermined to ensure that mutations were not introduced during PCR.
horseradish peroxidase-conjugated secondary antibody (KPL; 474–The 3xPEA3-luc reporter was constructed by isolating three of the four
1806), followed by incubation with Western Blot ChemiluminescencePEA3 binding sites from 4xPEA3-CAT [6] and cloning them into pGL3-
Reagent Plus (NEN Life Science Products) and exposure to X-ray filmBasic (Promega) to generate 3xPEA3-luc. The uPA-luc reporter plasmid
was a gift from Dr. Craig Hauser [34]. The 5xPEA3-luc reporter plasmid, (Kodak Scientific Imaging).
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